> Detailanzeige

Mateos, Maria-Victoria; Weisel, Katja; De Stefano, Valerio; Goldschmidt, Hartmut; Delforge, Michel; Mohty, Mohamad; Cavo, Michele; Vij, Ravi; Lindsey-Hill, Joanne; Dytfeld, Dominik; Angelucci, Emanuele; Perrot, Aurore; Benjamin, Reuben; van de Donk, Niels W. C. J.; Ocio, Enrique M.; Scheid, Christof; Gay, Francesca; Roeloffzen, Wilfried; Rodriguez-Otero, Paula; Broijl, Annemiek; Potamianou, Anna; Sakabedoyan, Caline; Semerjian, Maria; Keim, Sofia; [...]

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
  • Beteiligte: Mateos, Maria-Victoria; Weisel, Katja; De Stefano, Valerio; Goldschmidt, Hartmut; Delforge, Michel; Mohty, Mohamad; Cavo, Michele; Vij, Ravi; Lindsey-Hill, Joanne; Dytfeld, Dominik; Angelucci, Emanuele; Perrot, Aurore; Benjamin, Reuben; van de Donk, Niels W. C. J.; Ocio, Enrique M.; Scheid, Christof; Gay, Francesca; Roeloffzen, Wilfried; Rodriguez-Otero, Paula; Broijl, Annemiek; Potamianou, Anna; Sakabedoyan, Caline; Semerjian, Maria; Keim, Sofia; [...]
  • Erschienen: Springer Science and Business Media LLC, 2022
  • Erschienen in: Leukemia
  • Sprache: Englisch
  • DOI: 10.1038/s41375-022-01531-2
  • ISSN: 0887-6924; 1476-5551
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:p>Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (<jats:italic>N</jats:italic> = 248; ECOG performance status of 0–1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1–20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2–36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9–5.6) and 12.4 months (95% CI: 10.3–NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (<jats:italic>n</jats:italic> = 74), TEAEs (<jats:italic>n</jats:italic> = 19), and other reasons (<jats:italic>n</jats:italic> = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.</jats:p>